Monthly Prescribing Reference

Nipocalimab Designated Breakthrough Tx for Hemolytic Disease of the Fetus and Newborn

Nipocalimab is a fully human, anti-FcRn, aglycosylated IgG1 monoclonal antibody that reduces pathogenic alloantibodies in maternal circulation and blocks the placental transfer of maternal IgG to the ...
Monthly Prescribing Reference

Nipocalimab Gets Fast-Tracked for Hemolytic Disease of the Fetus and Newborn

The Food and Drug Administration (FDA) has granted Fast Track designation to nipocalimab (M281) for the prevention of hemolytic disease of the fetus and newborn (HDFN). The Food and Drug ...
Healio

Postnatal hemolytic disease management varies significantly worldwide, consensus needed

Please provide your email address to receive an email when new articles are posted on . Practice patterns vary widely for management of hemolytic disease of the fetus and newborn (HDFN). Researchers ...
Healio

Nipocalimab delays, prevents transfusions for pregnancies at risk for hemolytic disease

Please provide your email address to receive an email when new articles are posted on . Among pregnant women who received nipocalimab infusions, 54% had live births without an intrauterine transfusion ...